Quintiles
CompanyUnited StatesFounded 2016
Quintiles develops one asset, in phase 3 (Rexlemestrocel-L in chronic heart failure). Mostly cell therapy acting on inflammation and stem cell maintenance; based in the United States, founded in 2016.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 0
- Signals
Pipeline
1Allogeneic mesenchymal precursor cell therapy delivered with hyaluronic acid
Phase 3, Cell therapy, Inflammation, Stem cell maintenance, chronic heart failure, chronic low back pain, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials18
- Similar companies6